Pharmacologic rescue of hyperammonemia-induced toxicity in zebrafish by inhibition of ornithine aminotransferase

Matthias Zielonka1,2*, Maximilian Breuer1, Jürgen Günther Okun1, Matthias Carl3,4, Georg Friedrich Hoffmann1, Stefan Kölker1

1 University Hospital Heidelberg, Center for Child and Adolescent Medicine, Division for Pediatric Neurology and Metabolic Medicine, Heidelberg, Germany, 2 Heidelberg Research Center for Molecular Medicine (HRCMM), Heidelberg, Germany, 3 Heidelberg University, Medical Faculty Mannheim, Department of Cell and Molecular Biology, Mannheim, Germany, 4 University of Trento, Center for Integrative Biology (CIBIO), Laboratory of Translational Neurogenetics, Trento, Italy

* matthias.zielonka@med.uni-heidelberg.de

Abstract

Hyperammonemia is the common biochemical hallmark of urea cycle disorders, activating neurotoxic pathways. If untreated, affected individuals have a high risk of irreversible brain damage and mortality. Here we show that acute hyperammonemia strongly enhances transamination-dependent formation of osmolytic glutamine and excitatory glutamate, thereby inducing neurotoxicity and death in ammoniotelic zebrafish larvae via synergistically acting overactivation of NMDA receptors and bioenergetic impairment induced by depletion of 2-oxoglutarate. Intriguingly, specific and irreversible inhibition of ornithine aminotransferase (OAT) by 5-fluoromethylornithine rescues zebrafish from lethal concentrations of ammonium acetate and corrects hyperammonemia-induced biochemical alterations. Thus, OAT inhibition is a promising and effective therapeutic approach for preventing neurotoxicity and mortality in acute hyperammonemia.

Introduction

Nitrogen is an essential building block of amino and nucleic acids in all living organisms. Protein ingested by food or derived from the body is the major source of excess nitrogen once nitrogen-containing compounds are used to build energy substrates. Deamination of amino acids liberates ammonium (NH4+). If present in increased concentrations, NH4+ is highly toxic to living organisms. Species have developed different strategies to dispose excess NH4+. While fishes (ammoniotelic organisms) excrete up to 90% of their nitrogenous waste directly into their aqueous environment, reptiles and birds save water by excreting uric acid (uricotelic organisms) [1]. Humans and terrestrial animals (ureotelic organisms) are unable to excrete NH4+ directly or to package large amounts of NH4+ into uric acid and metabolize NH4+ to water-soluble urea, an energy-dependent mechanism requiring three moles of ATP for each mole of urea.
The urea cycle contains five enzymes and two transporters that are involved in the irreversible detoxification of NH$_4^+$ to urea including carbamoylphosphate synthetase 1 (CPS1), ornithine transcarbamylase (OTC), argininosuccinate synthetase 1 (ASS1), argininosuccinate lyase (ASL), arginase 1 (ARG1), citrin or aspartate/glutamate carrier and the mitochondrial ornithine transporter 1 [2]. Furthermore, carbonic anhydrase VA and N-acetylglutamate synthase (NAGS) are required to form bicarbonate and N-acetylglutamate for the first enzymatic step, the formation of carbamoylphosphate.

Urea cycle disorders (UCDs) are caused by inherited deficiencies of the NH$_4^+$-detoxifying ureagenetic machinery. Estimated cumulative incidence of UCDs is between 1:35,000 to 1:50,000 newborns [3, 4]. UCD patients, except for those with citrin and ARG1 deficiency, characteristically present with hyperammonemic encephalopathy (HE), which often manifests as early as the first days of life, but can present with first symptoms at any age afterwards. Onset type and the peak plasma ammonium concentration of the initial manifestation correlate with clinical severity and outcome. The most severe manifestation is neonatal HE with coma; it is associated with a high risk of mortality and, in survivors, of severe neurologic dysfunction and intellectual disability [3, 5–11].

Maintenance treatment of UCDs is based on a low protein diet, supplementation with essential amino acids, citrulline and/or arginine, and application of nitrogen scavenging drugs (sodium benzoate, sodium and glycerol phenylbutyrate) as well as carginic acid (for NAGS deficiency, partially responsive CPS1 deficiency and carbonic anhydrase VA deficiency). While low protein diet aims at reducing the production of nitrogenous waste, supplementation with citrulline (CPS1 and OTC deficiency, HHH syndrome) and/or arginine (for all UCDs except for NAGS and ARG1 deficiency) has been shown to stimulate the residual activity of the urea cycle in individuals with UCDs, maximizing ureagenesis and thus excretion of ammonium [2, 8]. Nitrogen scavengers bypass the urea cycle and thus exploit alternative pathways for excretion of waste nitrogen, thereby efficiently lowering plasma ammonium concentrations: Benzoate conjugates with glycine to generate hippurate and phenylacetate (following hepatic activation of its precursor phenylbutyrate) binds glutamine to form phenylacetylglutamine. Both conjugates, hippurate and phenylacetylglutamine, are water-soluble and renally excreted [2, 8]. For individuals with NAGS deficiency, partially responsive CPS1 deficiency and carbonic anhydrase VA deficiency administration of carginic acid has been proven beneficial, as it mimics the function of N-acetylglutamate, the physiological activator of CPS1, stimulating the formation of carbamoylphosphate [2, 12]. During HE, treatment is intensified stepwise by implementation of intravenous nitrogen scavenging therapy and extracorporeal detoxification using hemodialysis [2, 8, 13]. Liver transplantation is a curative therapy for UCDs. Best outcome is achieved if liver transplantation is carried out between age 3–12 months and before irreversible brain damage manifests [14, 15]. One of the major concerns is timely identification and undelayed start of severity-adjusted therapy. For this purpose, some UCDs—mostly ASS1 and ASL deficiencies—have been included in newborn screening (NBS) programs in a few countries [3, 16]. Its effectiveness remains to be demonstrated, since hyperammonemic crises often manifest before NBS results are available [16].

Despite several diagnostic and therapeutic improvements over the last three decades, the outcome of UCD patients with neonatal onset is still poor and has only slightly improved—if at all [7]. Neonatal mortality in severe forms is often as high as one third to one half of affected individuals [2, 3, 6]. Therefore, a better understanding of the underlying pathophysiology and the identification of novel targets for therapy are urgently required to improve the clinical outcome of UCD patients.

Here we show that zebrafish, an organism physiologically lacking the urea cycle at later stages of embryonic development, is a suitable model to study the mechanisms of NH$_4^+$-
induced toxicity and mortality and to investigate the efficacy of therapeutic interventions. Our finding that pharmacologic inhibition of ornithine aminotransferase (OAT) prevents mortality in zebrafish exposed to lethal NH$_4$+ concentrations, opens new therapeutic avenues for patients with UCDs.

**Materials and methods**

**Study approval**

All experiments, particularly with regard to expected mortality rates in the survival and therapeutic studies, complied with local and international regulations and ethics guidelines and were approved by the local research ethics committee (Germany, Regierungspräsidium Karlsruhe, permit AZ 35–9185.81/G-85/16). The study was performed in compliance with ARRIVE guidelines [17].

**Zebrafish maintenance**

Zebrafish were kept at 26 to 27˚C in a 14 hours (h) light and 10 h dark cycle. Embryos were collected by natural spawning and raised at 28.5˚C in E3 medium. The AB/AB wildtype strain was used for all experiments. Staging of embryos was done according to Kimmel et al. [18]. To inhibit pigmentation for subsequent in situ hybridization experiments, 0.2 mM 1-phenyl-2-thiourea was added at 1 day post fertilization (dpf).

**Model for acute hyperammonemia**

To study acute hyperammonemia, zebrafish larvae (N = 100 per group and experiment) at different developmental stages (0 dpf to 4 dpf) were exposed to 5, 10 or 20 mM ammonium acetate (NH$_4$Ac). As control for potential toxic effects of acetate, embryos were exposed to sodium acetate (NaAc) in parallel experiments using analogous concentrations. Survival was monitored by light microscopy every hour after start of exposure (NH$_4$Ac or NaAc) for a maximum of 36 h using cessation of heartbeat as primary endpoint. To further delineate underlying disease mechanisms on the biochemical and molecular level, zebrafish embryos/larvae at developmental stages 1 dpf or 4 dpf were exposed to either 10 mM NH$_4$Ac or NaAc for 6 or 12 h respectively, homogenized and subjected to subsequent analyses (qRT-PCR, amino acid analysis, quantification of 2-oxoglutarate, lactate or pyruvate). Since acute hyperammonemia in human neonates is associated with a high mortality rate of one third to one half of afflicted individuals and severe neurological sequelae in survivors [2, 3, 6], and to enable the delineation of underlying disease mechanisms including the efficacy testing of different therapeutic strategies with regard to survival, humane endpoints during the study period of 36 h were not defined. Mortality/survival rates are indicated in the respective results subsection using the Kaplan-Meier method. All exposed zebrafish embryos surving the observation period (36 h after start of exposure) were euthanized by addition of tricaine methanesulfonate (MS222) to the E3 medium to a final concentration of 300 mg/L. All scientific staff involved in zebrafish embryo handling and experiments have attended and successfully completed the “International Zebrafish and Medaka Course” at the Karlsruhe Institute of Technology, Germany, which is in compliance with the Federation for Laboratory Animal Science Associations (FELASA)—regulations and an equivalent of FELASA-B certificate.

**qRT-PCR**

Embryos were anesthetized with 0.01% tricaine methanesulfonate, and RNA was obtained by standard TRIzol Reagent (Invitrogen)-based procedure. Equal amounts of RNA from each sample (500 to 800 ng) were used for cDNA synthesis using Maxima first strand cDNA
synthesis kit (Thermo Fisher Scientific). PCR was performed on a CFX Connect™ Real-Time cycler (Biorad) (denaturation step: 95˚C for 25 sec, annealing and elongation step: 60˚C for 30 sec) using SensiFast SYBR™ Hi-ROX mix (Bioline) following the manufacturer’s instructions. The genes of interest were amplified with the following primers:

**GLULA**
GLULA-forward: 5’−TACTGACGGGACACCCCTTTG−3’
GLULA-reverse: 3’−CAACCTGGAATCCTCCACTGAG−5’

**GLULB**
GLULB-forward: 5’−CGAGGAAGGAGTTTGAAGCATA−3’
GLULB-reverse: 3’−AGCCCTTCTTTTCCTGACC−5’

**GLULC**
GLULC-forward: 5’−TCACAGAGTGCAATTGCTTAGG−3’
GLULC-reverse: 3’−CAGACCCCTCTCCAGACCAT−5’

**GLSA**
GLSA-forward: 5’−ATGACAAGAGAAGGAGGCAG−3’
GLSA-reverse: 3’−GCACCGTCTGAAGTGTTTTTC−5’

**GLS2B**
GLS2B-forward: 5’−CGACTACTCGGAGACATTCG−3’
GLS2B-reverse: 3’−CCAGCTCTCGACAGAGCAGA−5’

**GPT**
GPT-forward: 5’−GGCATAGCGTCAGTGTCTT−3’
GPT-reverse: 3’−AAGTCTGCCTCTGTTAGGTTG−5’

**GPT2**
GPT2-forward: 5’−CTTAAAGGGAGGTGGGAACAA−3’
GPT2-reverse: 3’−ATCCCTCGGGAACACTGGG−5’

**OAT**
OAT-forward: 5’−CGACACGCATCATGCTGAAC−3’
OAT-reverse: 3’−CAGACCTCCTCTGTTGTGTT−5’

**GRIN1a**
GRIN1a-forward: 5’−CATCCGGACGGCAATCTAC−3’
GRIN1a-reverse: 3’−CTTCTTTCTGGCAGCTGGCAG−5’

**GRIN1b**
GRIN1b-forward: 5’−CGGTCTCGTCCTTCTGATA−3’
GRIN1b-reverse: 3’−CGGTCTCGTCCTTCTGATA−5’

**GRIN2ab**
GRIN2ab-forward: 5’−CGAGCGATGAGGAGGATGTC−3’
GRIN2ab-reverse: 3’−AGGTTCCATGAGGATGTC−5’

**GRIN2da**
GRIN2da-forward: 5’−GTAGGCTTGTGTTGGAGAAGCG−3’
GRIN2da-reverse: 3’−AACATGTCTGTGTTGGAGAAGCG−5’

**GRIN3a**
GRIN3a-forward: 5’−GGCTCCACCCAGAAAGATT−3’
GRIN3a-reverse: 3’−CCAGGTCTTCTTTGCCCTCT−5’

The expression level of elongation factor 1-α was used for normalization.

### In situ hybridization (ISH) procedure
Specific antisense RNA probes were generated using a digoxigenin RNA labeling kit (Roche). Whole mount ISH of zebrafish larvae were carried out with standard procedures [19].
Corresponding sense probes were used as negative controls to confirm specificity of observed staining patterns. Stained embryos were mounted in glycerol for 24 h and imaged using a binocular microscope (MZ16 F, Leica).

**Preparation of whole embryo/larvae homogenates**

Zebrafish embryos or larvae were washed three times with ice-cold phosphate-buffered saline (PBS) and homogenized with a pestle in an appropriate size to allow disruption in a 1.5 mL Eppendorf tube and additional sonification. Lysates were centrifuged at 13,000 × g at 4˚C for 10 minutes (min). The supernatant was either subjected to downstream applications (e.g. amino acid analysis, quantitative analysis of 2-oxoglutarate or pyruvate and lactate) or stored at -80˚C until use. Protein concentrations were determined according to a modified Lowry protocol [20, 21] using bovine serum albumin as a standard.

**Amino acid analysis**

Amino acid content in whole embryo or larvae homogenates was quantitatively analyzed by high-performance liquid chromatography (HPLC). The amino acid concentrations of each sample were normalized to its protein content.

**Quantitative analysis of 2-oxoglutarate**

2-Oxoglutarate was determined in whole embryo or larvae homogenates using a commercially available colorimetric 2-oxoglutarate assay kit (Abcam) according to the manufacturer’s instructions. In this assay, 2-oxoglutarate is transaminated to pyruvate, which then is utilized to convert the optical density of a nearly colorless probe, thereby generating a colorimetric signal proportional to the 2-oxoglutarate content. Briefly, following washing with ice-cold PBS, control or NH₄Ac-exposed larvae were homogenized in 2-oxoglutarate assay buffer and centrifuged for 10 min at 13,000 × g at 4˚C in an Eppendorf centrifuge to remove insoluble material. The supernatant was transferred to a new Eppendorf tube and subjected to deproteinization using perchloric acid (PCA) in a final concentration of 1 M. To precipitate excess PCA and adjust the pH in the range of 6.5 to 8.0, ice-cold potassium hydroxide (2 M) was added. After centrifugation for 15 min at 13,000 × g at 4˚C, the supernatant was added to a 2-oxoglutarate converting enzyme mix and incubated for 30 min at 37˚C in the dark followed by colorimetric readout (optic density at a wavelength of 570 nm) using a SpectraMax Plus 384 microplate reader (Molecular Devices). To control for background signal, samples were additionally subjected to colorimetric readout in the absence of 2-oxoglutarate converting enzyme. Sample background values were subtracted from each sample reading for correction. The amount of 2-oxoglutarate was determined by extrapolation from a respective standard curve. For data consistency, measurements were performed in duplicates for each experimental series. 2-Oxoglutarate concentrations were normalized to the protein content.

**Quantitative analysis of pyruvate and lactate**

Pyruvate and lactate concentrations in homogenates of control or NH₄Ac-exposed larvae at 4 dpf were determined using a colorimetric enzymatic assay. Briefly, pyruvate content was analyzed by addition of NADH and lactate dehydrogenase to the homogenate using the lactate dehydrogenase reaction, which results in the formation of lactate and NAD⁺. Pyruvate concentrations were quantitatively determined by the reduction of NADH concentrations at 340 nm using an Olympus AU400 chemistry analyzer. Accordingly, lactate content was quantified using the lactate dehydrogenase reaction in reverse by measuring the increase of NADH
concentrations at the same wavelength. Pyruvate and lactate concentrations were normalized to the protein content in each sample.

Treatments
Zebrafish larvae at 4 dpf were preincubated for 30 min with 25 μM L-methionine sulfoximine (L-MSO; Sigma Aldrich), 50 μM ketamine (Sigma Aldrich) or 50 μM memantine (Sigma Aldrich) alone or in combination, or 5-fluoromethylornithine (5-FMO; ChemSpace) in a dose range from 50 to 200 μM. Hereafter, larvae were exposed to 10 mM NH₄Ac for 36 h and their survival monitored. For amino acid analyses or analysis of mRNA expression levels of NMDA receptor subunits, zebrafish larvae treated with or without 5-FMO in a dose range from 50 to 200 μM were homogenized 12 h after start of NH₄Ac exposure and subjected to HPLC or RNA extraction followed by qRT-PCR analysis. For quantification of phenotypic presentation, zebrafish larvae at developmental stage 4 dpf treated with or without 200 μM 5-FMO were exposed to 10 mM NH₄Ac for 12 h. Larvae were fixed in 5% PFA in PBS at 4˚C overnight and imaged using a binocular microscope (MZ16 F, Leica). The exposed cohorts with or without preincubation with 200 μM 5-FMO were compared to a non-exposed control group.

Statistical analysis
Data are expressed as mean +/- SD unless otherwise stated. Experiments were performed at least in triplicates. Differences between mean values of groups were evaluated by two-tailed Student’s t-test (two groups of samples) or ANOVA with a Tukey-Kramer post-test (multiple groups of samples) using the Prism software (GraphPad Software, La Jolla, CA, USA). Differences in survival rates were analyzed applying the log-rank test. P values <0.05 were considered significant.

Results
Ammonium acetate-induced mortality is age- and concentration-dependent
To assess whether developing zebrafish embryos are sensitive to NH₄⁺ we exposed them at different stages of embryonic development to varying concentrations of NH₄Ac and monitored survival during 36 h after start of exposure. Treatments of zebrafish larvae up to 1 dpf did not affect embryonic development or survival rates at any NH₄Ac concentration (5 to 20 mM) tested (Fig 1A). Similarly, embryos treated at 2 or 3 dpf were not affected (S1 Fig). In contrast, exposure at 4 dpf to NH₄Ac, induced death of all larvae (Fig 1B). Hyperammonemia-induced mortality was concentration-dependent (log-rank test, P<0.001). NH₄Ac-exposed larvae died within 32 h (5 mM NH₄Ac), 23 h (10 mM NH₄Ac) and 15 h (20 mM NH₄Ac), respectively, and showed a median survival of 27 h (5 mM NH₄Ac), 20 h (10 mM NH₄Ac) and 15 h (20 mM NH₄Ac), respectively (Fig 1B). In contrast, NaAc was not toxic to zebrafish larvae at any developmental stage (Fig 1C and 1D) excluding that the acetate compound contributes to the observed toxicity.

Acute hyperammonemia induces expression of glutamine synthetase and glutaminase
As NH₄Ac-mediated toxicity and mortality was evident not before 4 dpf, we hypothesized that developmental alterations establishing a genetic or metabolic cascade, which is sensitive to NH₄⁺, are responsible for the observed differences. Since cerebral glutamine-glutamate cycle is known to play a pivotal pathophysiological role in hyperammonemic conditions in humans.
[22] and was shown to be activated in a rat model of acute liver failure [23], we investigated whether glutamine synthetase and glutaminase were involved in NH₄Ac-induced mortality. In zebrafish, three paralogs of glutamine synthetases, i.e. GLULA, GLULB and GLULC, have been described [24], while four different isoforms of glutaminases, i.e. GLSA, GLSB, GLS2A and GLS2B, are known. Since the glutaminase isoform Glsa is selectively expressed in brain, whereas Gls2b is specifically expressed in the liver and the intestinal bulb, with expression starting at age 3 dpf in both [25], we have focused on these two isoforms.

To further address the relevance of glutamine synthetase isoforms, we performed a temporal and spatial expression analysis in the central nervous system (CNS) during zebrafish development using whole mount ISH. Expression of glutamine synthetase isoform Glula in radial glial cells [24] appeared not before 3 dpf with a further increase until 5 dpf, and thus parallels the observed hyperammonemia-induced neurotoxicity and mortality (Fig 2A). The paralog Glulb is expressed in distinct cells of the CNS at 1 dpf but remains to be restricted to peripheral parts of the midbrain after 3 dpf. Moreover, strong expression can be detected in neuromast cells and to a lower extent in defined parts of the CNS up to 5 dpf [24] (Fig 2B). In contrast, Glulc is absent from the CNS and only expressed in distinct cell types of the nostrils (Fig 2C).

Representative images of negative control stainings using the respective Glula, Glulb and Glulc sense-probes are illustrated in S2 Fig. Results of the temporal (overall) expression analysis of

Fig 1. Kaplan-Meier plots of ammonium acetate-induced mortality. Zebrafish larvae (n = 100 per group) at 1 or 4 dpf were exposed to varying concentrations (5, 10 and 20 mM) of either NH₄Ac or NaAc and survival rates monitored for up to 36 h. While NH₄Ac was not toxic to zebrafishes at 1 dpf (A), exposure at 4 dpf induced death of all larvae in a dose-dependent manner (log-rank test, P < 0.001) (B). In contrast, NaAc had virtually no toxic or lethal effect at either developmental stage (C, D).

https://doi.org/10.1371/journal.pone.0203707.g001
glutamine synthetases Glula, Glulb and Glulc as well as glutaminase isoforms Glsa and Gls2b are depicted in S3 Fig.

Interestingly, while there was no induction of gene expression of glutamine synthases or glutaminases evident in exposed zebrafish larvae at 1 dpf as judged by qRT-PCR experiments, expression of Glula, Glulb as well as Glsa and Gls2b was significantly increased in NH\textsubscript{4}+ exposed larvae at 4 dpf compared to untreated and NaAc-exposed controls (Fig 3A and 3B).

Acute hyperammonemia leads to massive increase in glutamate and glutamine concentrations and depletion of alanine and ornithine

Next, we studied the effects of acute hyperammonemia on amino acids by HPLC. In larvae at 1 dpf, NH\textsubscript{4}Ac exposure (10 mM) for 6 h caused a decrease in glutamate with concomitant increase in glutamine concentrations (glutamate/glutamine ratio: 0.88) demonstrating increased glutamine synthesis from glutamate as initial adaptation to acute hyperammonemia. Other amino acid levels remained unaltered. Notably, glutamine and glutamate concentrations gradually normalized after 12 h of NH\textsubscript{4}Ac exposure, while urea formation was increased when compared to the control cohort at this developmental age (Fig 4A and 4B).

In striking contrast to the biochemical changes observed in zebrafish larvae at 1 dpf, exposed larvae at 4 dpf exhibited simultaneously elevated glutamate and glutamine concentrations (glutamate/glutamine ratio: 1.20) after 6 and 12 h exposure, respectively. In addition, hyperammonemia caused a depletion of essential branched-chain amino acids, as well as alanine, ornithine and subsequently arginine levels (Fig 4C and 4D).
Transamination via ornithine and alanine aminotransferases are pivotal processes in acute hyperammonemia

Since glutamine synthesis is the only detoxification strategy of the brain for the detoxification of ammonium [26, 27] which is characterized by the condensation of glutamate and ammonium to form glutamine, massively elevated glutamate concentrations as observed in our experiments were unexpected. As increased glutamate concentrations in acute hyperammonemia were associated with depletion of alanine and ornithine, we hypothesized that transamination processes via alanine and ornithine aminotransferases were responsible for the observed biochemical changes. In zebrafish, two homologs of alanine aminotransferases, GPT and GPT2, have been annotated [28, 29], while for ornithine aminotransferase only one single isoform, OAT, has been predicted by genome sequence analysis (NM_001317170.1). To further address our hypothesis, we performed a temporal expression analysis of alanine and ornithine aminotransferases during zebrafish development. Interestingly, while Gpt was expressed with only mild variation throughout whole embryonic development, Gpt2 exhibits strong maternal expression with a decrease at 75% epiboly. In contrast, Oat expression constantly increased during neurulation, peaking at 5 dpf (S4 Fig).

Subsequently, we analyzed the regulation of gene expression of aminotransferases under hyperammonemic conditions. While mRNA expression of Gpt was unaltered in zebrafish larvae exposed at 4 dpf, Gpt2 expression was significantly increased after 12 h of NH₄Ac exposure.
Interestingly, exposed zebrafish larvae already exhibited a significant increase in Oat expression after 6 h, with a further elevation up to 3.5-fold after 12 h as compared to non-exposed control (Fig 5C). These findings highlight an adaptive regulatory gene induction of the ammonium-metabolizing transaminases Gpt2 and Oat. While GPT2 reversibly catalyzes the transfer of an amino group from alanine to 2-oxoglutarate to form glutamate and pyruvate, OAT generates glutamate and Δ1-pyrroline-5-carboxylate by transfer of the delta-amino group of ornithine to 2-oxoglutarate [30, 31].

To confirm that the activities of GPT2 and OAT are indeed functionally relevant for the observed changes in amino acid patterns (e.g. glutamate increase, depletion of alanine and...
ornithine), we investigated pyruvate, lactate and 2-oxoglutarate concentrations upon NH₄Ac exposure. As expected, acute hyperammonemia caused a significant increase of both pyruvate and lactate. In addition, 2-oxoglutarate concentrations massively depleted in zebrafish larvae exposed to NH₄Ac at 4 dpf (Fig 5D, 5E and 5F).

Glutamatergic signaling via NMDA receptors is mediating neurotoxicity in acute hyperammonemia

Since pathologically increased glutamate concentrations in the brain are known to induce neurotoxicity mainly via excessive activation of NMDA receptors [32], we further investigated the effect of acute hyperammonemia on the expression levels of specific NMDA receptor subunits. In zebrafish, five different NMDA receptor subunits, i.e. GRIN1a, GRIN1b, GRIN2ab, GRIN2da and GRIN3a, have been described [33]. In the first step, we analyzed the temporal expression of NMDA receptor isoforms during zebrafish development on the mRNA level. While Grin1a, Grin1b, Grin2da and Grin3a were hardly expressed at early developmental stages, their expression strongly increased at 5 dpf (Fig 6A) coinciding with the time point of hyperammonemia-induced neurotoxicity and mortality. In acute hyperammonemia, zebrafish larvae exposed to NH₄Ac at 4 dpf displayed a significant downregulation of the gene expression of NMDA receptor subunits Grin1a, Grin1b and Grin2da (Fig 6B), most likely accounting
Fig 6. Glutamatergic signaling via NDMA receptors mediates neurotoxicity in acute hyperammonemia. Endogenous mRNA expression of zebrafish homologs of NDMA receptor subunits (Grin1a, Grin1b, Grin2ab, Grin2da and Grin3a) during zebrafish development (50% epiboly to 5 dpf). Expression of Grin1a, Grin1b, Grin2da and Grin3a strongly increased at 5 dpf (A), coinciding with the time point of NH₄⁺-induced mortality. Larvae exposed to 10 mM NH₄Ac at 4 dpf displayed a downregulated gene expression of NMDA receptor subunits Grin1a, Grin1b and Grin2da after 6 and 12 h, respectively (B). Data are expressed as mean +/- SD in fold-change (whole body lysates, n = 3 with 50 larvae per group and experiment; ANOVA, *P<0.05, **P<0.01).

https://doi.org/10.1371/journal.pone.0203707.g006
for a compensatory mechanism to reduce the toxic effects of elevated glutamate concentrations in brain.

**OAT inhibition prevents neurotoxicity and mortality in acute hyperammonemia**

Since glutamine synthesis and NMDA receptor-mediated signaling is thought to play an important role in hyperammonemia-induced neurotoxicity and since our experiments unraveled hyperammonemia-induced changes in the expression pattern of these components, we wondered whether their therapeutic modulation could protect zebrafish larvae against NH₄Ac-induced toxicity and death. Therefore, we next investigated the therapeutic efficacy of pharmacologic inhibition of glutamine synthesis or/and NMDA receptor signaling in acute hyperammonemia using the glutamine synthetase inhibitor L-MSO and the NMDA receptor antagonists memantine and ketamine, alone or in combination. However, treatment with either of the compounds had only limited beneficial effects on survival rates: While mock-treated zebrafish larvae at 4 dpf died within 21 h (median survival: 17 h), larvae preincubated with 25 μM L-MSO or ketamine succumbed to 10 mM NH₄Ac within 24 h (median survival: 21.5 h) or 25 h (median survival: 22 h), respectively. Treatment with 25 μM memantine was more beneficial for survival rates (time to total lethality: 27 h; median survival: 22 h) when compared to L-MSO or ketamine (Fig 7A). The combination of L-MSO and memantine did not further increase survival rates as opposed to the treatment with memantine alone (Fig 7B).

To assess whether OAT inhibition might be a more effective therapeutic strategy against hyperammonemia-induced toxicity and mortality, we tested 5-FMO, a specific and irreversible OAT inhibitor [34]. Indeed, zebrafish larvae at 4 dpf preincubated with 50 μM 5-FMO 30 min prior to NH₄Ac exposure survived significantly longer as opposed to the mock-treated cohort (Fig 7C). While mock-treated zebrafish larvae succumbed to 10 mM NH₄Ac within 20 h (median survival: 16 h), 50 μM 5-FMO prolonged survival up to 31 h (median survival: 27 h; log-rank test, P<0.0001). In addition, further dosage escalation of 5-FMO had an incremental benefit on the survival rates of the treated zebrafish cohorts. While 72% of larvae preincubated with 100 μM 5-FMO survived the observation period of 36 h of NH₄Ac exposure, the survival rate of larvae treated with 200 μM 5-FMO was further increased to 91% (Fig 7C). Furthermore, treatment with 200 μM 5-FMO rescued hyperammonemia-induced brain cell death as determined by light microscopy (Fig 7D). Whereas in the mock-treated cohort 71% of larvae exhibited morphological signs of brain damage 12 h after exposure to 10 mM NH₄Ac, the phenotypic occurrence was reduced to 6% by treatment with 200 μM 5-FMO (Fig 7E).

Notably, in acute hyperammonemia treatment with 5-FMO restored ornithine and arginine concentrations and led to a normalization of glutamate and glutamine concentrations (Fig 8A and 8B) with subsequent correction of Grin1a and Grin1b receptor expression (Fig 8C and 8D). These results clearly indicate that OAT inhibition is an effective and promising therapeutic strategy preventing neurotoxicity and mortality in a zebrafish model of acute hyperammonemia.

**Discussion**

In this study, we established a zebrafish model for acute hyperammonemia by exposing zebrafish larvae to defined concentrations of NH₄Ac. Acute hyperammonemia led to a transamination-dependent increase of osmolytic glutamine and glutamate concentrations and decreased mRNA expression for different NMDA receptor subunits, which suggests that hyperammonemia induces neurotoxicity and death via excessive activation of NMDA receptors. Inhibition of OAT using 5-FMO corrected biochemical alterations and significantly prolonged survival
rates of exposed zebrafish larvae, while none of the other therapeutic interventions, i.e. inhibition of glutamine synthetase (L-MSO) and NMDA receptors (ketamine, memantine), was able to rescue ammonium-exposed zebrafish larvae.

Zebrafish belongs to a subgroup of teleost fish species that are capable of producing significant levels of urea during early embryonic development owing to the presence of a functional urea cycle, but become ammoniotelic with further developmental age [35, 36]. In developing zebrafish larvae, the five enzyme transcripts necessary for ureagenesis (CPS1, OTC, ASS1, ASL and ARG1) are co-expressed in the embryonic endoderm adjacent to the anterior part of the
yolk sac and the floor plate from 5 hpf up to 48 hpf [36]. Ureagenesis and urea excretion peaks at 48 hpf and is reduced significantly thereafter, while direct ammonium excretion increases constantly after hatching at 2 to 3 dpf [35, 36]. Injections of a morpholino targeting the rate-limiting enzyme CPS1 led to a significant reduction of urea excretion and whole urea body content in the injected zebrafish larvae up to 48 hpf, demonstrating that ureagenesis indeed is performed by a functional urea cycle in early embryonic development [36]. Consistently, we found that exposure of zebrafish larvae with 10 mM NH$_4^+$ at 24 hpf but not at subsequent stages significantly triggered ureagenesis. This result supports the idea of a temporarily active urea cycle before hatching. After hatching zebrafish larvae become primarily ammoniotelic with direct excretion of NH$_4^+$ ions into the aqueous environment. This adaptation is achieved by the timely and spatial expression of proteins belonging to the family of membrane-bound rhesus (Rh) glycoproteins. The proteins, first described in erythrocytes, increase the ammonium permeability of the plasma membrane and act as specific ammonium transporters [37]. The members of the Rh protein family known to transport ammonium across the cell membrane are Rh-associated glycoprotein (Rhag), Rh B glycoprotein (Rhbg) and Rh C glycoprotein (Rhcg). The expression of those three ammonium transporters constantly increases during zebrafish embryonic development peaking between 3 and 4 dpf [34]. All three transporters

![Fig 8. OAT-inhibition corrects biochemical alterations and NMDA receptor expression in acute hyperammonemia.](https://doi.org/10.1371/journal.pone.0203707.g008)
localize to the gill filaments and distinct cells on the outer surface of the yolk sac at 4 dpf, the latter suggesting the presence of Rh glycoproteins within a specific cell type on the skin [35]. Morpholino-based knock-down experiments for each of the Rh glycoproteins induced a significantly decreased ammonium excretion and subsequent ammonium accumulation in whole body lysates, confirming their crucial role for ammonium excretion after hatching until adulthood [35]. Since zebrafish larvae lack a functional urea cycle after hatching, they endogenously mimic the metabolic situation of patients with UCDs who suffer from the functional consequences of defective ureagenesis. Moreover, increasing the concentration of NH$_4^+$ ions in the water by addition of NH$_4$Ac is a convenient way to induce acute hyperammonemia in zebrafish larvae [38]. This approach enabled us to investigate the effects of toxic ammonium concentrations on biochemical and gene regulation as well as survival in a per se urea cycle-deficient organism including the efficacy of different therapeutic interventions.

The pathophysiological basis of NH$_4^+$ toxicity to the brain was shown to be caused by NH$_4^+$-induced alterations in several metabolic pathways. Mice deficient for the urea cycle enzyme OTC exhibit decreased ATP and creatine content in brain as sign of cerebral energy depletion [39, 40]. Analogously, primary astrocyte cultures develop mitochondrial permeability transition upon NH$_4^+$ exposure resulting in cessation of ATP synthesis, production of reactive oxygen species and cell death [41, 42]. In addition, hyperammonemia increases osmotically active cerebral glutamine concentrations via astrocytic glutamine synthetase activity, which ultimately results in cytotoxic brain edema by astrocyte swelling [43, 44], a key finding that could also be verified in patients with UCDs by in vivo magnetic resonance spectroscopy [45]. Consistently, we observed a strong increase of glutamine in zebrafish exposed to NH$_4$Ac at 4 dpf which was associated with gene induction of the metabolizing isoforms of glutamine synthetases, Glula and Glulb. In contrast to humans, the CNS of the zebrafish is characterized by the presence of radial glia instead of stellate or round astrocytes, which to some degree exert astrocyte-like functions. Mammalian astrocytes are functionally involved in neuronal injury response, the maintenance of ionic and osmotic balance and integrity of the blood-brain-barrier as well as the regulation of blood flow and synapse function [46–49]. Zebrafish radial glia are known to express the water transport-protein aquaporin-4 and additional markers of tight junctions, which are distinctive for human astrocytes [50, 51]. In light of glutamate transporter Eaat2b expression that colocalizes with Glula expression in the zebrafish CNS [52], the adaptive increase of glutamine concentrations together with gene induction of glutamine synthetases and glutaminases upon NH$_4^+$ exposure indicates that zebrafish larvae possess a metabolically active cerebral glutamine-glutamate-cycle. Strikingly, hyperammonemia caused a massive elevation of glutamate concentrations associated with depletion of ornithine and 2-oxoglutarate, pointing at transamination processes via OAT as important pathophysiological basis of NH$_4^+$-induced toxicity. Cataplerotic withdrawal of 2-oxoglutarate from the tricarboxylic acid (TCA) cycle due to glutamate synthesis has been proposed as a relevant factor for the observed energy depletion in hyperammonemia [53]. Increased pyruvate and lactate concentrations in the exposed zebrafish cohort again indicated that ATP is generated to a higher extent via anaerobic glycolysis suggesting impairment of TCA cycle flux. Increased lactate concentrations have also been observed in a rat model of acute liver failure as well as in primary astrocytes exposed to NH$_4^+$ [54]. Finally, HE is associated with decreased oxygen consumption in vivo [55, 56].

Glutamate is the major excitatory neurotransmitter of the mammalian brain by activating either ionotropic NMDA and α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors or metabotropic glutamate (mGlu1 to mGlu8) receptors [57, 58]. Excess production of glutamate at the synapse or inhibition of its reuptake from the synaptic cleft leads to an excessive stimulation of glutamate receptors, most importantly NMDA receptors,
and consecutive calcium overload, shortage of ATP, mitochondrial dysfunction, increased oxidative stress resulting in excitotoxicity and cell death of adjacent neurons [59–63]. Thus, for proper neuronal functioning and prevention of neurotoxicity, it is essential for the organism to maintain extracellular cerebral glutamate concentrations within the normal range [64, 65]. Considerable evidence has been gathered demonstrating glutamate-induced neurotoxicity to be also a prominent pathophysiological factor in neurodegenerative diseases such as Huntington disease [66], Parkinson disease [67, 68] and amyotrophic lateral sclerosis [69, 70] as well as in acute insults to the brain including cerebral ischemia [71], perinatal brain injury [72] and epilepsy [73]. Our data indicate that excessive transamination-dependent glutamate production and cerebral glutamate accumulation with consecutive NMDA receptor-mediated neurotoxicity is a central pathophysiological hallmark of acute hyperammonemic conditions.

Accordingly, in vitro NH$_4^+$ exposure of primary astrocytes and neuronal cultures induces glutamate release from astrocytes, inhibition of glutamate reuptake by astrocytes and excessive depolarization of glutamatergic neurons [74, 75]. Moreover, it has been shown that hyperammonemia is associated with increased synaptic glutamate release and an increased net formation of glutamate in different animal models in vivo [76–78], clearly supporting our findings. The selective downregulation of NMDA receptor subunits Grin1a, Grin1b and Grin2da observed in NH$_4^+$-exposed zebrafish larvae at 4 dpf most likely accounts for a compensatory mechanism to reduce the toxic effects of elevated cerebral glutamate concentrations by downsizing NMDA receptor-mediated signaling. As GRIN1a and GRIN1b are the subunits forming the Ca$^{2+}$ channel of the NMDA receptor complex, their selective downregulation might represent an efficient adaptation process to suppress downstream events (e.g. alterations affecting NO metabolism, ATP shortage, mitochondrial dysfunction) induced by increased Ca$^{2+}$ influx. A similar process involving decreased NMDA receptor density has been reported in rat and mouse models of acute and chronic hyperammonemia [79, 80]. This compensatory mechanism, however, fails at acute exposure to high ammonium concentrations like in our study.

Current therapeutic strategies in hyperammonemic decompensation of patients with UCDs are mainly based on nitrogen scavenging by intravenous administration of sodium benzoate and sodium or glycero1 phenylbutyrate, forming water-soluble and dialyzable benzoyl glycine (hippuric acid) and phenylacetylglutamine. These nitrogen scavengers are effective in lowering the concentration of ammonia by binding glycine and glutamine in the periphery, but do not directly interfere with secondary metabolic alterations in the brain (e.g. glutamatergic excitotoxicity and bioenergetic impairment), which ultimately result in brain damage and death.

Modulation of impaired glutamatergic neurotransmission has already been proposed as therapeutic concept in neurological diseases. Translational activators of glutamate transporter 1 (GLT1), such as ceftriaxone and LDN/OSU-0212320 have significant protective effects in animal models of amyotrophic lateral sclerosis and epilepsy [81, 82]. For hyperammonemic conditions, NMDA receptor antagonists MK-801 and 2-amino-5-phosphonovaleric acid improve neuronal survival in primary cortical neurons of newborn rats exposed to NH$_4^+$ [83]. NMDA receptor antagonists MK-801 and memantine have demonstrated neuroprotective properties in a rat model of acute liver failure increasing the percentage of surviving animals from 23% to 62%. However, this effect was restricted to animals suffering from mild acute liver failure [63]. Moreover, it has been shown that transient blockade of NMDA receptors induces apoptotic neurodegeneration in the developing brain of late fetal and neonatal rats [84]. Similarly, NMDA receptor blockade using the NMDA receptor antagonist memantine or ketamine slightly improved survival of NH$_4^+$-exposed zebrafish larvae in our study. Inhibition of glutamine synthetase to ultimately attenuate glutamine-mediated brain edema in acute hyperammonemia by application of L-MSO alone or in combination with memantine,
however, did not further increase survival time proving that inhibition of cerebral glutamine synthetase has also a limited therapeutic efficacy for NH₄⁺-exposed zebrafish.

Given the therapeutic limitations of glutamine synthetase inhibition and NMDA receptor blockade, we assumed that lowering brain glutamate concentrations by inhibition of OAT-mediated transamination could be an alternative approach to minimize cerebral glutamate excitotoxicity in acute hyperammonemia. Interestingly, a comparable approach involving transamination processes has already been used to attenuate glutamate excitotoxicity in a rat model of ischemic stroke. Administration of recombinant human aspartate aminotransferase to the animals was shown to lower serum and brain glutamate concentrations, which resulted in a significant reduction of stroke-induced infarct volume and sensorimotor deficit [85].

5-FMO is an irreversible, specific inhibitor of OAT competing with endogenous ornithine for the catalytic site of the enzyme [34]. *In vitro* determination of residual OAT activity after incubation with increasing concentrations of 5-FMO revealed pseudo-first-order inactivation kinetics with an apparent dissociation constant $K_i$ of 70 μM. Mice injected intraperitoneally with 5-FMO in an effective concentration of 10 mg/kg body weight exhibited OAT inactivation to a maximum residual activity of 10 to 20%, which was resistant to further inactivation by higher or repeated doses [34]. Treatment of zebrafish larvae with 5-FMO not only normalized glutamate and consecutively glutamine concentrations, but also restored ornithine and arginine levels in a dose-dependent manner. Moreover, expression of NMDA receptor sub-units *Grin1a* and *Grin1b* subsequently normalized upon treatment with 5-FMO, indicating efficient correction of altered glutamatergic neurotransmission in acute hyperammonemia. Adverse effects of treatment with 5-FMO were not observed. In our model system, therapeutic OAT inhibition was even by far superior to NMDA receptor blockade and inhibition of glutamine synthetase. More than 90% of exposed NH₄Ac-exposed zebrafish survived an otherwise lethal dosage. This remarkable therapeutic efficiency owes to the position of OAT in intermediary metabolism linking 2-oxoglutarate metabolism and the TCA cycle to glutamatergic neurotransmission. As inhibition of OAT transamination activity in acute hyperammonemia leads to normalization of glutamate and glutamine levels consecutively restoring 2-oxoglutarate concentrations, it is a valuable therapeutic strategy to simultaneously tackle impaired glutamatergic neurotransmission, glutamine-mediated brain edema and cerebral energy depletion, which are the central culprits of hyperammonemia-induced neurotoxicity.

Therapeutic effects of OAT inhibition on reliable hard clinical endpoints such as brain damage and mortality in acute hyperammonemia have not been investigated in animal models before. Thus, our zebrafish model is exclusive in showing prevention of neurotoxicity and significantly prolonged survival times *in vivo*. Whether these promising beneficial effects of OAT inhibition on survival also hold true for mammalian organisms needs to be determined in future research. Given that inherited OAT deficiency is characterized by gyrate atrophy of the choroid and retina [86], long-term OAT inhibition as therapeutic strategy might bear the risk of inducing iatrogenic gyrate atrophy. Therefore, it would be desirable that new reversible inhibitors leading to a transient OAT inhibition will be developed for clinical use.

**Conclusion**

Our finding that pharmacologic OAT inhibition prevents mortality in zebrafish exposed to lethal NH₄⁺ concentrations opens new therapeutic avenues for individuals with UCDs, who are confronted with a lifetime risk of irreversible brain damage and death resulting from hyperglutaminergic and hyperglutamatergic hyperammonemia, a neurotoxic and often lethal biochemical triad.
S1 Fig. Kaplan-Meier plots of ammonium acetate-induced mortality at developmental stages 2 and 3 dpf. Zebrafish larvae (n = 100 per group) at 2 or 3 dpf were exposed to varying concentrations (5, 10 and 20 mM) of either NH₄Ac or NaAc and survival rates monitored for up to 36 h. While zebrafish larvae did not succumb to NH₄Ac in a dose range of 5 to 10 mM at either developmental stage (A, C), 20 mM NH₄Ac induced death of 46% of exposed larvae at 3 dpf until the end of the observation period (log-rank test, P < 0.001). Intriguingly, NH₄- induced toxicity started not earlier than 24 h after start of exposure, equaling developmental stage 4 dpf of the exposed zebrafish cohort (C). NaAc had no toxic effect at either developmental stage (B, D).

S2 Fig. Negative control whole mount ISH of GLULA, GLULB and GLULC during zebrafish development. ISH was performed using sense-probes for the respective glutamine synthetase isoforms. Pictures are representative images of 3 independent experiments (n = 50 embryos/larvae per stage and experiment). Images show the embryonic heads at stages indicated. Left columns of each row show latter with anterior to the left and right columns with anterior to the top. Negative control ISH did not show any specific staining for each of the sense-probes used (A-C).

S3 Fig. Relative mRNA expression of glutamine synthetases GLULA, GLULB and GLULC and glutaminases GLSA and GLS2B during zebrafish development. Glula showed a biphasic expression pattern with increased expression peaking at 75% epiboly followed by a consecutive decrease with a second peak appearing at 5 dpf (A). In contrast, Glulb and Glulc were both maternally delivered exhibiting decreasing expression during gastrulation (B, C). While Glulc remained hardly expressed during subsequent developmental stages (C), Glulb expression constantly increased after 24 hpf peaking at 5 dpf (B). Glsa expression constantly increased during neurulation with an expression peak at 5 dpf (D), whereas Gls2b displayed an exclusive expression peak at 5 dpf (E). Data are expressed as mean +/- SD in fold-change (whole body lysates, n = 3 with 50 larvae per group and experiment).

S4 Fig. Relative mRNA expression of transaminases GPT, GPT2 and OAT during zebrafish development. Gpt was expressed with only mild variation throughout whole embryonic development (A), whereas Gpt2 exhibited highest expression levels during early gastrulation with a decrease at 75% epiboly (B). In contrast, Oat expression constantly increased during neurulation, peaking at 5 dpf (C). Data are expressed as mean +/- SD in fold-change (whole body lysates, n = 3 with 50 larvae per group and experiment).

Acknowledgements
We thank S. Sauer, S. Jung-Klawitter and all members of the Kölker laboratory for helpful suggestions and discussions and S. Exner for technical assistance. We also thank F. Kratzer, K. Schwarz and P. Feyh at the Metabolic Center Heidelberg for expert technical support.

Author Contributions
Conceptualization: Matthias Zielonka, Stefan Kölker.
**Data curation:** Matthias Zielonka, Jürgen Günther Okun, Stefan Kölker.

**Formal analysis:** Matthias Zielonka, Maximilian Breuer, Jürgen Günther Okun, Matthias Carl, Stefan Kölker.

**Funding acquisition:** Matthias Zielonka, Georg Friedrich Hoffmann.

**Investigation:** Matthias Zielonka, Maximilian Breuer.

**Methodology:** Matthias Zielonka, Matthias Carl.

**Project administration:** Matthias Zielonka, Jürgen Günther Okun, Matthias Carl, Georg Friedrich Hoffmann, Stefan Kölker.

**Resources:** Matthias Carl.

**Supervision:** Jürgen Günther Okun, Matthias Carl, Georg Friedrich Hoffmann, Stefan Kölker.

**Validation:** Matthias Zielonka, Matthias Carl, Georg Friedrich Hoffmann, Stefan Kölker.

**Visualization:** Matthias Zielonka, Maximilian Breuer.

**Writing – original draft:** Matthias Zielonka, Stefan Kölker.

**Writing – review & editing:** Matthias Zielonka, Maximilian Breuer, Jürgen Günther Okun, Matthias Carl, Georg Friedrich Hoffmann.

**References**

1. Wood C. Ammonia and urea metabolism and excretion. The Physiology of Fishes, edited by Evans DE: Boca Raton, FL, CRC; 1993. p. 379–427.

2. Haberle J, Boddart N, Burlina A, Chakrapani A, Dixon M, Huemer M, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J Rare Dis. 2012; 7:32. https://doi.org/10.1016/j.ymgme.2013.07.008 PMID: 23972786

3. Nettesheim S, Kolker S, Karall D, Haberle J, Posset R, Hoffmann GF, et al. Incidence, disease onset and short-term outcome in urea cycle disorders -cross-border surveillance in Germany, Austria and Switzerland. Orphanet J Rare Dis. 2017; 12(1):111. https://doi.org/10.1186/s13023-017-0661-x PMID: 28619060

4. Summar ML, Koelker S, Freedenberg D, Le Mons C, Haberle J, Lee HS, et al. The incidence of urea cycle disorders. Mol Genet Metab. 2013; 110(1–2):179–80. https://doi.org/10.1016/j.ymgme.2013.07.008 PMID: 23972786

5. Ah Mew N, Krivitzky L, McCarter R, Batshaw M, Tuchman M, Urea Cycle Disorders Consortium of the Rare Diseases Clinical Research N. Clinical outcomes of neonatal onset proximal versus distal urea cycle disorders do not differ. J Pediatr. 2013; 162(2):324–9 e1. https://doi.org/10.1016/j.jpeds.2012.06.065 PMID: 22901741

6. Bachmann C. Outcome and survival of 88 patients with urea cycle disorders: a retrospective evaluation. Eur J Pediatr. 2003; 162(6):410–6. https://doi.org/10.1007/s00431-003-1188-9 PMID: 12684900

7. Burgard P, Kolker S, Haege G, Lindner M, Hoffmann GF. Neonatal mortality and outcome at the end of the first year of life in early onset urea cycle disorders—review and meta-analysis of observational studies published over more than 35 years. J Inherit Metab Dis. 2016; 39(2):219–29. https://doi.org/10.1007/s10545-015-9901-1 PMID: 26634836

8. Enns GM, Berry SA, Berry GT, Rhead WJ, Brusilow SW, Hamosh A. Survival after treatment with phe- nylacetate and benzoxae for urea-cycle disorders. N Engl J Med. 2007; 356(22):2282–92. https://doi. org/10.1056/NEJMoar066596 PMID: 17538087

9. Kolker S, Garcia-Cazorla A, Valayannopoulos V, Lund AM, Burlina AB, Sykut-Cegielksa J, et al. The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 1: the initial presentation. J Inherit Metab Dis. 2015; 38(6):1041–57. https://doi.org/10.1007/s10545-015-9839-3 PMID: 25875215

10. Summar ML, Dobelaere D, Brusilow S, Lee B. Diagnosis, symptoms, frequency and mortality of 260 patients with urea cycle disorders from a 21-year, multicentre study of acute hyperammonaemic episodes. Acta Paediatr. 2008; 97(10):1420–5. https://doi.org/10.1111/j.1651-2227.2008.00952.x PMID: 18647279
11. Unsinn C, Das A, Valayannopoulos V, Thimm E, Beblo S, Burlina A, et al. Clinical course of 63 patients with neonatal onset urea cycle disorders in the years 2001–2013. Orphanet J Rare Dis. 2016; 11(1):116. https://doi.org/10.1186/s13023-016-0493-0 PMID: 27538463

12. van Karnebeek CD, Sly WS, Ross CJ, Salvarinova R, Yapitto-Lee J, Santra S, et al. Mitochondrial carbonic anhydrase VA deficiency resulting from CA5A alterations presents with hyperammonemia in early childhood. Am J Hum Genet. 2014; 94(3):453–61. https://doi.org/10.1016/j.ajhg.2014.01.006 PMID: 24530203

13. Husson MC, Schiff M, Fouilloux A, Cano A, Dobbelaeere D, Brassier A, et al. Efficacy and safety of i.v. sodium benzoate in urea cycle disorders: a multicentre retrospective study. Orphanet J Rare Dis. 2016; 11(1):127. https://doi.org/10.1186/s13023-016-0513-0 PMID: 27663197

14. McBride KL, Miller G, Carter S, Karpen S, Goss J, Lee B. Developmental outcomes with early orthotopic liver transplantation for infants with neonatal-onset urea cycle defects and a female patient with late-onset ornithine transcarbamylase deficiency. Pediatrics. 2004; 114(4):e523–6. https://doi.org/10.1542/peds.2004-0198 PMID: 15466081

15. Moroika D, Kasahara M, Takada Y, Shirouzu Y, Taira K, Sakamoto S, et al. Current role of liver transplantation for the treatment of urea cycle disorders: a review of the worldwide English literature and 13 cases at Kyoto University. Liver Transpl. 2005; 11(11):1332–42. https://doi.org/10.1002/lt.20587 PMID: 16237708

16. Posset R, Garcia-Cazorla A, Valayannopoulos V, Teles EL, Dionisi-Vici C, Brassier A, et al. Age at disease onset and peak ammonium level rather than interventional variables predict the neurological outcome in urea cycle disorders. J Inherit Metab Dis. 2016; 39(5):661–72. https://doi.org/10.1007/s10545-016-9938-9 PMID: 27106216

17. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, Group NCRRGW. Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol. 2010; 160(7):1577–9. https://doi.org/10.1111/j.1476-5381.2010.00872.x PMID: 20649561

18. Kimmel CB, Ballard WW, Kimmel SR, Ullmann B, Schilling TF. Stages of embryonic development of the zebrafish. Dev Dyn. 1995; 203(3):253–310. https://doi.org/10.1002/aja.1002030302 PMID: 8589427

19. Thissie C, Thissie B. High-resolution in situ hybridization to whole-mount zebrafish embryos. Nat Protoc. 2008; 3(1):59–69. https://doi.org/10.1038/nprot.2007.514 PMID: 18193022

20. Helenius A, Simons K. The binding of detergents to lipophilic and hydrophilic proteins. J Biol Chem. 1972; 247(11):3656–61. PMID: 4131126

21. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951; 193(1):265–75. PMID: 14907713

22. Bak LK, Schousboe A, Waagepetersen HS. The glutamate/GABA-glutamine cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer. J Neurochem. 2006; 98(3):641–53. https://doi.org/10.1111/j.1471-4159.2006.03913.x PMID: 16787421

23. Singh S, Mondal P, Trigun SK. Acute liver failure in rats activates glutamine-glutamate cycle but declines antioxidant enzymes to induce oxidative stress in cerebral cortex and cerebellum. PLoS One. 2014; 9(4):e95855. https://doi.org/10.1371/journal.pone.0095855 PMID: 24755687

24. Dhanasiri AK, Fernandes JM, Kiron V. Glutamine synthetase activity and the expression of three glul paralogues in zebrafish during transport. Comp Biochem Physiol B Biochem Mol Biol. 2012; 163(3–4):274–84. https://doi.org/10.1016/j.cbpb.2012.06.003 PMID: 22750401

25. Furukawa F, Tseng YC, Liu ST, Chou YL, Lin CC, Sung PH, et al. Induction of Phosphoenolpyruvate Carboxykinase (PEPCK) during Acute Acidosis and Its Role in Acid Secretion by V-ATPase-Expressing Ionocytes. Int J Biol Sci. 2015; 11(6):712–25. https://doi.org/10.7150/ijbs.11827 PMID: 25999794

26. Hakvoort TB, He Y, Kulik W, Vermeulen JL, Duijsters JT, Ruijter JM, et al. Pivotal role of glutamine synthetase in ammonia detoxification. Hepatology. 2017; 65(1):281–93. https://doi.org/10.1002/hep.28852 PMID: 27641632

27. Skarpetas A, Mawal Y, Qureshi IA. Developmental study of hepatic glutamine synthetase in a mouse model of congenital hyperammonemia. Biochem Mol Biol Int. 1997; 43(1):133–9. PMID: 9315291

28. Miranda AC, Fang P, Williams TF, Baldor LC, Howe AK, Ebert AM, et al. Aminocyl-tRNA synthetase dependent angiogenesis revealed by a bioengineered macrolide inhibitor. Sci Rep. 2015; 5:13160. https://doi.org/10.1038/srep13160 PMID: 26271225

29. Steinke D, Salzburger W, Braasch I, Meyer A. Many genes in fish have species-specific asymmetric rates of molecular evolution. BMC Genomics. 2006; 7:20. https://doi.org/10.1186/1471-2164-7-20 PMID: 16466575

30. Benuck M, Lajtha A. Aminotransferase activity in brain. Int Rev Neurobiol. 1975; 17:85–129. PMID: 2378448

31. Zimmerman HJ. Serum Enzymes in the Diagnosis of Hepatic Disease. Gastroenterology. 1964; 46:613–8. PMID: 14156921
32. Paoletti P. Molecular basis of NMDA receptor functional diversity. Eur J Neurosci. 2011; 33(8):1351–65. https://doi.org/10.1111/j.1460-9568.2011.07628.x PMID: 21935862
33. Cox JA, Kucenas S, Voigt MM. Molecular characterization and embryonic expression of the family of N-methyl-D-aspartate receptor subunit genes in the zebrafish. Dev Dyn. 2005; 234(3):756–66. https://doi.org/10.1002/dvdy.20532 PMID: 16123982
34. Daune G, Gerhart F, Seiler N. 5-Fluoromethylornithine, an irreversible and specific inhibitor of L-ornithine:2-oxo-acid aminotransferase. Biochem J. 1988; 253(2):481–8. PMID: 3178724
35. Braun MH, Steele SL, Ekker M, Perry SF. Nitrogen excretion in developing zebrafish (Danio rerio): a role for Rh proteins and urea transporters. Am J Physiol Renal Physiol. 2009; 296(5):F994–F1005. https://doi.org/10.1152/ajphen.90656.2008 PMID: 19279128
36. LeMoine CM, Walsh PJ. Ontogeny of ornithine-urea cycle gene expression in zebrafish (Danio rerio). Am J Physiol Regul Integr Comp Physiol. 2013; 304(11):R991–1000. https://doi.org/10.1152/ajpregu.00411.2012 PMID: 23576614
37. Marin AM, Boeckstaens M, Benjelloun F, Cherif-Zahar B, Andre B. Structural involvement in substrate recognition of an essential aspartate residue conserved in Mep/Amt and Rh-type ammonium transporters. Curr Genet. 2006; 49(6):364–74. https://doi.org/10.1007/s00294-006-0062-5 PMID: 16477434
38. Feldman B, Tuchman M, Caldovic L. A zebrafish model of hyperammonemia. Mol Genet Metab. 2014; 113(1–2):142–7. https://doi.org/10.1016/j.ymgme.2014.07.001 PMID: 25069822
39. Ratnakumar L, Qureshi IA, Butterworth RF. Effects of congenital hyperammonemia on the cerebral and hepatic levels of the intermediates of energy metabolism in spf mice. Biochem Biophys Res Commun. 1992; 184(2):746–51. PMID: 1575747
40. Ratnakumar L, Qureshi IA, Butterworth RF, Marescau B, De Deyn PP. Arginine-related guanidino compounds and nitric oxide synthase in the brain of ornithine transcarbamylase deficient spf mutant mouse: effect of metabolic arginine deficiency. Neurosci Lett. 1996; 215(3):153–6. PMID: 8899736
41. Alvarez VM, Rama Rao KV, Brahmbhatt M, Norenb erg MD. Interaction between cytokines and ammonia in the mitochondrial permeability transition in cultured astrocytes. J Neurosci Res. 2011; 89(12):2028–40. https://doi.org/10.1002/jnr.22708 PMID: 21748779
42. Bai G, Rama Rao KV, Murthy CR, Panickar KS, Jayakumar AR, Norenberg MD. Ammonia induces the mitochondrial permeability transition in primary cultures of rat astrocytes. J Neurosci Res. 2001; 66(5):981–91. https://doi.org/10.1002/jnr.10056 PMID: 11746427
43. Bachmann C, Braissant O, Villard AM, Boulat O, Henry H. Ammonia toxicity to the brain and creatine. Mol Genet Metab. 2004; 81 Suppl 1:SS2–7.
44. Inoue I, Gushiken T, Kobayashi K, Saheki T. Accumulation of large neutral amino acids in the brain of ornithine transcarbamylase deficiency spf mutant mouse: effect of metabolic arginine deficiency. Neurosci Lett. 1996; 215(3):153–6. PMID: 8899736
45. Connelly A, Cross JH, Gadian DG, Hunter JV, Kirkham FJ, Leonard JV. Magnetic resonance spectroscopy shows increased brain glutamine in ornithine carbamoyl transferase deficiency. Pedi atr Res. 1993; 33(1):77–81. https://doi.org/10.1203/00006450-199301000-00016 PMID: 8438866
46. Attwell D, Buchan AM, Charpak S, Lauritzen M, Macvicar BA, Newman EA. Glial and neuronal control of brain blood flow. Nature. 2010; 468(7321):232–43. https://doi.org/10.1038/nature09613 PMID: 21068832
47. Bouzier-Sore AK, Pellerin L. Unraveling the complex metabolic nature of astrocytes. Front Cell Neurosci. 2013; 7:179. https://doi.org/10.3389/fncel.2013.00179 PMID: 24130515
48. Gregg JM, DePaul MA, Filous AR, Lang BT, Tran A, Silver J. Functional regeneration beyond the glial scar. Exp Neurol. 2014; 253:197–207. https://doi.org/10.1016/j.expneurol.2013.12.024 PMID: 24424280
49. Dallerac G, Chever O, Rouach N. How do astrocytes shape synaptic transmission? Insights from electrophysiology. Front Cell Neurosci. 2013; 7:159. https://doi.org/10.3389/fncel.2013.00159 PMID: 24101894
50. Corbo CP, Othman NA, Gutkin MC, Alonso Adel C, Fulop ZL. Use of different morphological techniques to analyze the cellular composition of the adult zebrafish optic tectum. Microsc Res Tech. 2012; 75(3):325–33. https://doi.org/10.1002/jemt.21061 PMID: 21823204
51. Grupp L, Wolburg H, Mack AF. Astroglial structures in the zebrafish brain. J Comp Neurol. 2010; 518(21):4277–87. https://doi.org/10.1002/cne.22481 PMID: 20835506
52. McKeown KA, Moreno R, Hall VL, Ribera AB, Downes GB. Disruption of Eaat2b, a glutamate transporter, results in abnormal motor behaviors in developing zebrafish. Dev Biol. 2012; 362(2):162–71. https://doi.org/10.1016/j.ydbio.2011.11.001 PMID: 22094018
53. Bessman SP, Bessman AN. The cerebral and peripheral uptake of ammonia in liver disease with an hypothesis for the mechanism of hepatic coma. J Clin Invest. 1955; 34(4):622–8. https://doi.org/10.1172/JCI103111 PMID: 14367516
54. Zwingmann C, Chatatuer N, Leibfritz D, Butterworth RF. Selective increase of brain lactate synthesis in experimental acute liver failure: results of a [H-C] nuclear magnetic resonance study. Hepatology. 2003; 37(2):420–8. https://doi.org/10.1053/jhep.2003.50052 PMID: 12540793

55. Dam G, Keiding S, Munk OL, Ott P, Vilstrup H, Bak LK, et al. Hepatic encephalopathy is associated with decreased cerebral oxygen metabolism and blood flow, not increased ammonia uptake. Hepatology. 2013; 57(1):258–65. https://doi.org/10.1002/hep.23995 PMID: 22886493

56. Strauss G, Moller K, Larsen FS, Kondrup J, Knudsen GM. Cerebral glucose and oxygen metabolism in patients with fulminant hepatic failure. Liver Transpl. 2003; 9(12):1244–52. https://doi.org/10.1016/j.lts.2003.09.020 PMID: 14625823

57. Dingleline R, Borges K, Bowie D, Traynelis SF. The glutamate receptor ion channels. Pharmacol Rev. 1999; 51(1):7–61. PMID: 10049997

58. Greenamyre JT, Porter RH. Anatomy and physiology of glutamate in the CNS. Neurology. 1994; 44(11 Suppl 8):S7–13.

59. Braissant O. Current concepts in the pathogenesis of urea cycle disorders. Mol Genet Metab. 2010; 100 Suppl 1:S3–S12.

60. Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron. 1988; 1(8):623–34. PMID: 2908446

61. Olney JW. Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. Science. 1969; 164(3880):719–21. PMID: 5778021

62. Olney JW, Sharpe LG. Brain lesions in an infant rhesus monkey treated with monosodium glutamate. Science. 1969; 166(3903):386–8. PMID: 5812037

63. Rodrigo R, Cauil O, Boix J, EImill N, Agusti A, Felipo V. Role of NMDA receptors in acute liver failure and ammonia toxicity: therapeutical implications. Neurochem Int. 2009; 55(1–3):113–8. https://doi.org/10.1016/j.neuint.2009.01.007 PMID: 19428814

64. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med. 1994; 330(9):613–22. https://doi.org/10.1056/NEJM199403033300907 PMID: 7905600

65. Meldrum B, Garthwaite J. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci. 1990; 11(9):379–87. PMID: 2238094

66. Andre VM, Cecpeda C, Levine MS. Dopamine and glutamate in Huntington’s disease: A balancing act. CNS Neurosci Ther. 2010; 16(3):163–78. https://doi.org/10.1111/j.1755-5949.2010.00134.x PMID: 20406248

67. Ambrosi G, Cerri S, Blandini F. A further update on the role of excitotoxicity in the pathogenesis of Parkinson’s disease. J Neural Transm (Vienna). 2014; 121(8):849–59. https://doi.org/10.1007/s00702-013-1149-z PMID: 24380931

68. Meredith GE, Totterdell S, Beales M, Meshul CK. Impaired glutamate homeostasis and programmed cell death in a chronic MPTP mouse model of Parkinson’s disease. Exp Neurol. 2009; 219(1):334–40. https://doi.org/10.1016/j.expneurol.2009.06.005 PMID: 19523952

69. Blasco H, Mavel S, Corcia P, Gordon PH. The glutamate hypothesis in ALS: pathophysiology and drug development. Curr Med Chem. 2014; 21(31):3551–75. PMID: 25245510

70. Rothstein JD, Tsai G, Kuncl RW, Clawson L, Cornblath DR, Drachman DB, et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol. 1990; 28(1):18–25. https://doi.org/10.1002/ana.410280106 PMID: 2375630

71. Camacho A, Massieu L. Role of glutamate transporters in the clearance and release of glutamate during ischemia and its relation to neuronal death. Arch Med Res. 2006; 37(1):11–8. https://doi.org/10.1016/j.arcmed.2005.05.014 PMID: 16314180

72. Johnston MV. Excitotoxicity in perinatal brain injury. Brain Pathol. 2005; 15(3):234–40. PMID: 16196390

73. Coulter DA, Eid T. Astrocytic regulation of glutamate homeostasis in epilepsy. Glia. 2012; 60(8):1215–26. https://doi.org/10.1002/glia.22341 PMID: 22592998

74. Cagnon L, Braissant O. Hyperammonemia-induced toxicity for the developing central nervous system. Brain Res Rev. 2007; 56(1):183–97. https://doi.org/10.1016/j.brainresrev.2007.06.026 PMID: 17881060

75. Chan H, Hazell AS, Desjardins P, Butterworth RF. Effects of ammonia on glutamate transporter (GLAST) protein and mRNA in cultured rat cortical astrocytes. Neurochem Int. 2000; 37(2–3):243–8. PMID: 10812209

76. de Knegt RJ, Schalm SW, van der Rijk CC, Fekkes D, Dalm E, Heekin-Weyma I. Extracellular brain glutamate during acute liver failure and during acute hyperammonemia simulating acute liver failure: an experimental study based on in vivo brain dialysis. J Hepatol. 1994; 20(1):19–26. PMID: 7911135
77. Michalak A, Rose C, Butterworth J, Butterworth RF. Neuroactive amino acids and glutamate (NMDA) receptors in frontal cortex of rats with experimental acute liver failure. Hepatology. 1996; 24(4):908–13. https://doi.org/10.1002/hep.510240425 PMID: 8855196

78. Moroni F, Lombardi G, Moneti G, Cortesini C. The release and neosynthesis of glutamic acid are increased in experimental models of hepatic encephalopathy. J Neurochem. 1983; 40(3):850–4. PMID: 6131108

79. Rao VL, Agrawal AK, Murthy CR. Ammonia-induced alterations in glutamate and muscimol binding to cerebellar synaptic membranes. Neurosci Lett. 1991; 130(2):251–4. PMID: 1686641

80. Ratnakumari L, Qureshi IA, Butterworth RF. Loss of [3H]MK801 binding sites in brain in congenital ornithine transcarbamylase deficiency. Metab Brain Dis. 1995; 10(3):249–55. PMID: 8830285

81. Fontana AC. Current approaches to enhance glutamate transporter function and expression. J Neurochem. 2015; 134(6):982–1007. https://doi.org/10.1111/jnc.13200 PMID: 26096891

82. Takahashi K, Foster JB, Lin CL. Glutamate transporter EAAT2: regulation, function, and potential as a therapeutic target for neurological and psychiatric disease. Cell Mol Life Sci. 2015; 72(18):3489–506. https://doi.org/10.1007/s00018-015-1937-8 PMID: 26033496

83. Klejman A, Wegrzynowicz M, Szatmari EM, Mioduszewska B, Hetman M, Albrecht J. Mechanisms of ammonia-induced cell death in rat cortical neurons: roles of NMDA receptors and glutathione. Neurochem Int. 2005; 47(1–2):51–7. https://doi.org/10.1016/j.neuint.2005.04.006 PMID: 15985217

84. Ikonomidou C, Bosch F, Miksa M, Bittigau P, Vockler J, Dikranian K, et al. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science. 1999; 283(5398):70–4. PMID: 9872743

85. Perez-Mato M, Ramos-Cabrero P, Sobrino T, Blanco M, Ruban A, Mirelman D, et al. Human recombinant glutamate oxaloacetate transaminase 1 (GOT1) supplemented with oxaloacetate induces a protective effect after cerebral ischemia. Cell Death Dis. 2014; 5:e992. https://doi.org/10.1038/cddis.2013.507 PMID: 24407245

86. Simell O, Takki K. Raised plasma-ornithine and gyrate atrophy of the choroid and retina. Lancet. 1973; 1(7811):1031–3. PMID: 4122112